Patient selection for transplantation in the myelodysplastic syndromes

Hematology/Oncology Clinics of North America

Volumn 24, Issue 2, 2010, Pages 469-476

  Cutler, Corey ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Allogeneic; Myelodysplastic syndromes; Stem cell transplantation

Indexed keywords

FERRITIN;

ALLOGENEIC STEM CELL TRANSPLANTATION; COMORBIDITY; CYTOGENETICS; DISEASE ACTIVITY; DISEASE CLASSIFICATION; ERYTHROCYTE TRANSFUSION; FERRITIN BLOOD LEVEL; HIGH RISK PATIENT; HUMAN; INTERNATIONAL PROSTATE SYMPTOM SCORE; MORTALITY; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT SELECTION; PRIORITY JOURNAL; REVIEW; TREATMENT DURATION;

AGED; AGED, 80 AND OVER; COHORT STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MYELODYSPLASTIC SYNDROMES; PATIENT SELECTION; RISK; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TIME FACTORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 77950548224     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2010.02.006     Document Type: Review

References (22)

1. Cibmtr Report on state of the art in blood and marrow transplantation Available at:, Accessed 2009. http://www.cibmtr.org/SERVICES/Observational_Research/Summary_Slides/index.html.
2. Nachtkamp K., Kundgen A., Strupp C., et al. Impact on survival of different treatments for myelodysplastic syndromes (MDS). Leuk Res 2009, 33:1024-1028.
3. Deeg H.J., Storer B., Slattery J.T., et al. Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. Blood 2002, 100:1201-1207.
4. de Witte T., Brand R., Van Biezen A., et al. Allogeneic stem cell transplantation for patients with refractory anaemia with matched related and unrelated donors: delay of the transplant is associated with inferior survival. Br J Haematol 2009, 146:627-636.
5. Cutler C.S., Lee S.J., Greenberg P., et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood 2004, 104:579-585.
6. Garcia-Manero G., Shan J., Faderl S., et al. A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia 2008, 22:538-543.
7. Platzbecker U., Bornhauser M., Germing U., et al. Red blood cell transfusion dependence and outcome after allogeneic peripheral blood stem cell transplantation in patients with de novo myelodysplastic syndrome (MDS). Biol Blood Marrow Transplant 2008, 14:1217-1225.
8. Malcovati L., Porta M.G., Pascutto C., et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 2005, 23:7594-7603.
9. Malcovati L., Germing U., Kuendgen A., et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007, 25:3503-3510.
10. Alessandrino E.P., Della Porta M.G., Bacigalupo A., et al. WHO classification and WPSS predict post-transplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Blood 2008, 112:895-902.
11. Armand P., Kim H.T., Cutler C.S., et al. Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood 2007, 109:4586-4588.
12. Pullarkat V., Blanchard S., Tegtmeier B., et al. Iron overload adversely affects outcome of allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2008, 42:799-805.
13. Haase D., Germing U., Schanz J., et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood 2007, 110:4385-4395.
14. Mills K.I., Kohlmann A., Williams P.M., et al. Microarray-based classifiers and prognosis models identify subgroups with distinct clinical outcomes and high risk of AML transformation of myelodysplastic syndrome. Blood 2009, 114:1063-1072.
15. Della Porta M.G., Malcovati L. Clinical relevance of extrahematologic comorbidity in the management of patients with myelodysplastic syndrome. Haematologica 2009, 94:602-606.
16. Sorror M.L., Maris M.B., Storb R., et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005, 106:2912-2919.
17. Zipperer E., Pelz D., Nachtkamp K., et al. The hematopoietic stem cell transplantation comorbidity index is of prognostic relevance for patients with myelodysplastic syndrome. Haematologica 2009, 94:729-732.
18. Sorror M.L., Sandmaier B.M., Storer B.E., et al. Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. J Clin Oncol 2007, 25:4246-4254.
19. Oliansky D.M., Antin J.H., Bennett J.M., et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of myelodysplastic syndromes: an evidence-based review. Biol Blood Marrow Transplant 2009, 15:137-172.
20. Alyea E.P., Kim H.T., Ho V., et al. Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome. Biol Blood Marrow Transplant 2006, 12:1047-1055.
21. Martino R., Iacobelli S., Brand R., et al. Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. Blood 2006, 108:836-846.
22. Fenaux P., Mufti G.J., Hellstrom-Lindberg E., et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009, 10:223-232.